Search research articles
Contact Us
Filters
Showing results (331-340 of 356) with videos related to
Page
of 36
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection
Curtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
The Pediatric Infectious Disease Journal
|
December 15, 2010
Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial
Matthew D Snape, Chaam L Klinger, Elvis D Daniels, et al.
Journal of the Pediatric Infectious Diseases Society
|
March 17, 2023
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
Eric A F Simões, Nicola P Klein, Charu Sabharwal, et al.
The New England Journal of Medicine
|
September 15, 2021
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R Falsey, Robert W Frenck, Edward E Walsh, et al.
Pediatrics
|
August 3, 2001
Natural history of neonatal herpes simplex virus infections in the acyclovir era
D W Kimberlin, C Y Lin, R F Jacobs, et al.
Pediatrics
|
August 3, 2001
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections
D W Kimberlin, C Y Lin, R F Jacobs, et al.
Nature
|
August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Edward E Walsh, Robert Frenck, Ann R Falsey, et al.
Nature
|
January 20, 2021
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
Page
of 36
Search research articles
Search
Showing results (331-340 of 356) with videos related to
Sort By:
Page
of 36
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection
Curtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
The Pediatric Infectious Disease Journal
|
December 15, 2010
Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial
Matthew D Snape, Chaam L Klinger, Elvis D Daniels, et al.
Journal of the Pediatric Infectious Diseases Society
|
March 17, 2023
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
Eric A F Simões, Nicola P Klein, Charu Sabharwal, et al.
The New England Journal of Medicine
|
September 15, 2021
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R Falsey, Robert W Frenck, Edward E Walsh, et al.
Pediatrics
|
August 3, 2001
Natural history of neonatal herpes simplex virus infections in the acyclovir era
D W Kimberlin, C Y Lin, R F Jacobs, et al.
Pediatrics
|
August 3, 2001
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections
D W Kimberlin, C Y Lin, R F Jacobs, et al.
Nature
|
August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine
|
October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Edward E Walsh, Robert Frenck, Ann R Falsey, et al.
Nature
|
January 20, 2021
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
Page
of 36